Incubate Launches Policy Lab Under New Leadership and Releases IP White Paper
2024年4月26日 - 10:30PM
Today, on World Intellectual Property Day, Incubate is excited to
launch Incubate Policy Lab under the guidance of senior advisor
Kirsten Axelsen. Kirsten brings over two decades of leadership
experience in the life sciences industry. Accompanying the launch
is a new white paper examining the important role intellectual
property protections play in biopharmaceutical development.
"We launched Incubate Policy Lab to explore the various impacts
policy decisions can have on innovation and investment in the life
sciences industry," said Incubate executive director John Stanford.
"The Policy Lab will provide regular updates from the venture
capital perspective on the outsized role policy plays in bringing
innovative treatments to patients in need."
In the coming months, Incubate Policy Lab -- the research arm of
Incubate -- plans to release additional reports and white papers
focused on issues at the intersection of policymaking, venture
investment, and drug development.
The newest white paper, titled "Intellectual Property for
Medicines: Supporting Innovation and Promoting Competition" and
penned by Axelsen, explains the various patent protections and
regulatory exclusivities available to novel small molecule and
biological therapies. The paper also details how a recent policy
proposal related to patent licensing agreements between
universities and the private sector could weaken the investment
climate for the life sciences industry.
"We're delighted to release this new white paper from Incubate
Policy Lab," Axelsen said. "We hope this resource and future Policy
Lab papers will demonstrate to policymakers the need for informed
decision-making that prioritizes both innovation and access."
The white paper can be found at Incubate Policy Lab.
###
About IncubateIncubate is a 501(c)(4) organization of
venture capital firms representing the patient, corporate, and
investment communities. Our primary aim is to educate policymakers
on the role of venture capital in bringing promising treatments to
patients in need.
Lucia Orlandi
Incubate
202-970-9745
lucia@keybridge.biz